← All trials
NCT04408664
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Oct 31, 2021
- Completion date
- Mar 31, 2022
- First posted
- May 29, 2020
- Last posted
- May 29, 2020
- Enrollment
- 75
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Katholieke Universiteit LeuvenLead sponsor
- Hasselt UniversityCollaborator
- Algemeen Ziekenhuis Maria MiddelaresCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.